DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea

Completed

Conditions: Ovarian Neoplasms

First Posted Date: 2020-10-19

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 662

Registration Number: NCT04589039

Locations: 🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Anaplastic Lymphoma Kinase

Interventions: Other: No Intervention

First Posted Date: 2020-10-19

Last Posted Date: 2025-01-15

Lead Sponsor: Takeda

Target Recruit Count: 257

Registration Number: NCT04592523

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

Study of TAK-672 in Participants With Acquired Hemophilia A

Phase 2

Completed

Conditions: Acquired Hemophilia A

Interventions: Biological: TAK-672

First Posted Date: 2020-10-08

Last Posted Date: 2024-12-02

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT04580407

Locations: 🇯🇵
Gunma University Hospital, Maebashi, Gunma, Japan
🇯🇵
Nagoya University Hospital, Aichi, Nagoya, Japan
🇯🇵
Nara Medical University Hospital, Kashihara-shi, Nara, Japan

and more 6 locations

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TAK-788
Drug: Antidiarrheal prophylaxis

First Posted Date: 2020-10-06

Last Posted Date: 2020-12-17

Lead Sponsor: Takeda

Registration Number: NCT04576208

Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

Completed

Conditions: Crohn Disease
Inflammatory Bowel Diseases
Colitis, Ulcerative

Interventions: Other: No Intervention

First Posted Date: 2020-09-28

Last Posted Date: 2024-03-15

Lead Sponsor: Takeda

Target Recruit Count: 7873

Registration Number: NCT04567628

Locations: 🇨🇦
Takeda Canada, Toronto, Ontario, Canada

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Phase 2

Completed

Conditions: Postoperative Nausea and Vomiting (PONV)

Interventions: Drug: TAK-951
Drug: Ondansetron
Drug: TAK-951 Placebo
Drug: Ondansetron Placebo

First Posted Date: 2020-09-21

Last Posted Date: 2023-04-21

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT04557189

Locations: 🇺🇸
Stony Brook Medicine - Hospital, Stony Brook, New York, United States
🇺🇸
Phoenix Clinical Research, Tamarac, Florida, United States
🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States

and more 4 locations

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-994
Drug: Placebo

First Posted Date: 2020-09-16

Last Posted Date: 2021-01-19

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT04551079

Locations: 🇺🇸
Clinilabs Drug Development Corporation, New York, New York, United States

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Phase 2

Active, not recruiting

Conditions: Celiac Disease

Interventions: Drug: Placebo
Drug: TAK-101
Dietary Supplement: Gluten

First Posted Date: 2020-08-28

Last Posted Date: 2025-05-06

Lead Sponsor: Takeda

Target Recruit Count: 17

Registration Number: NCT04530123

Locations: 🇺🇸
Cadena Care Institute, Inc., Poway, California, United States
🇺🇸
Asthma and Allergy Associates, PC, Colorado Springs, Colorado, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 45 locations

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: Lanadelumab

First Posted Date: 2020-08-07

Last Posted Date: 2022-03-07

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT04503603

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
Ph+ Mixed Phenotype Acute Leukemia (MPAL)
Philadelphia Chromosome-Like ALL (Ph-like ALL)

Interventions: Drug: Ponatinib
Drug: Chemotherapy Agents

First Posted Date: 2020-08-06

Last Posted Date: 2025-01-15

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT04501614

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy